Synapse - Jose Baselga

Results (92)

PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancer

Journal Article

Majewski, I. J.; Nuciforo, P.; Mittempergher, L.; Bosma, A. J.; Eidtmann, H.; Holmes, E.; Sotiriou, C.; Fumagalli, D.; Jimenez, J.; Aura, C.; more...
Journal of Clinical Oncology (2015)

Fulltext@MSK | Save

Reply to A. Avan et al

Journal Article

Baselga, J.; Clark, E.; Kiermaier, A.; Swain, S. M.
Journal of Clinical Oncology (2015)

Fulltext@MSK | Save

Phase II study of paclitaxel given once per week along with trastuzumab and pertuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer

Journal Article

Dang, C.; Iyengar, N.; Datko, F.; D'Andrea, G.; Theodoulou, M.; Dickler, M.; Goldfarb, S.; Lake, D.; Fasano, J.; Fornier, M.; more...
Journal of Clinical Oncology (2015)

Fulltext@MSK | Save

First-in-human phase I "basket" study of Debio1347 (CH5183284), a novel FGFR inhibitor, in patients FGFR genoinically activated advanced solid tumors

Meeting Abstract

Voss, M. H.; Adamo, B.; Heist, R. S.; Gandhi, L.; Moulon, C.; Tanaka, H.; Ishii, N.; Vasiln, A.; Aoki, Y.; Nicolas-Metral, V.; more...
Journal of Clinical Oncology (2014)

Fulltext@MSK | Save

VE-BASKET, a Simon 2-stage adaptive design, phase II, histology-independent study in nonmelanoma solid tumors harboring BRAF V600 mutations (V600m): Activity of vemurafenib (VEM) with or without cetuximab (CTX) in. colorectal cancer (CRC)

Meeting Abstract

Tabernero, J.; Chan, E.; Baselga, J.; Blay, J. Y.; Chau, I.; Hyman, D. M.; Raje, N. S.; Wolf, J.; Sirzén, F.; Veronese, M. L.; more...
Journal of Clinical Oncology (2014)

Fulltext@MSK | Save

Phase I trial of daily PI3K alpha inhibitor BYL719 plus letrozole (L) or exemestane (E) for patients (pts) with hormone receptor-positive (HR plus ) metastatic breast cancer (MBC)

Meeting Abstract

Shah, P. D.; Modi, S.; Datko, F. M.; Moynahan, M. E.; Zamora, S.; D'Andrea, G.; Lake, D.; Goldfarb, S. B.; Patil, S.; Singh, S.; more...
Journal of Clinical Oncology (2014)

Fulltext@MSK | Save

A phase 1 study of LJM716 in patients with esophageal squamous cell carcinoma, bead and neck cancer, or HER2-overexpressing metastatic breast or gastric cancer

Meeting Abstract

Reynolds, K. L.; Juric, D.; Baselga, J.; Alsina, M.; Tabernero, J.; Bedard, P. L.; Graham, D. M.; Gonzalez-Angulo, A. M.; Garrido-Laguna, I.; Sharma, S.; more...
Journal of Clinical Oncology (2014)

Fulltext@MSK | Save

First results from the phase III ALTTO trial (BIG 2-06; NCCTG [Alliance] N063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (T -> L), or their combination (T plus L) in the adjuvant treatment of HER2-positive early breast cancer (EBC)

Meeting Abstract

Piccart-Gebhart, M. J.; Holmes, A. P.; Baselga, J.; de Azambuja, E.; Dueck, A. C.; Viale, G.; Zujewski, J. A.; Goldhirsch, A.; Santillana, S.; Pritchard, K. I.; more...
Journal of Clinical Oncology (2014)

Fulltext@MSK | Save

Monitoring PIK3CA mutant allele fraction (AF) in cell-free DNA (cfDNA) in metastatic breast cancer (MBC) patients treated with PI3K alpha-inhibitor plus letrozole (L) or exemestane (E)